Clinical Trial Update: Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

View source ↗

Summary

An update from an AstraZeneca-sponsored trial in systemic lupus erythematosus notes achievement of LLDAS5 with anifrolumab. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Lupus Erythematosus, Systemic | Status: RECRUITING